Prospective Cohort With Hemopathy in Languedoc-Roussillon
HemoDiag
Prospective Cohort Study of Clinical and Laboratory Data of Patients With Hemopathy in Languedoc-Roussillon
1 other identifier
observational
500
1 country
1
Brief Summary
Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2014
CompletedFirst Submitted
Initial submission to the registry
April 22, 2014
CompletedFirst Posted
Study publicly available on registry
May 9, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2033
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2033
January 4, 2022
December 1, 2021
19.3 years
April 22, 2014
December 31, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Survival with 2 years
Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC\_QLQ-C30
2 years
Secondary Outcomes (2)
Survival with 5 years
5 years
Survival with 10 years
10 years
Study Arms (1)
hematologic malignancy
hematologic malignancy with a sampling of blood
Interventions
hematologic malignancy with a sampling of blood
Eligibility Criteria
patient for suspected haematological disease and justifying further exploration
You may qualify if:
- Age over 18
- Consultant or hospitalized patient for suspected malignant hemopathy and justifying further exploration or patient with a diagnosis of malignant hemopathy less than 6 months old at the time of signing the consent
- Having signed an informed consent
- Affiliated with a social security scheme
You may not qualify if:
- Minor or major protected
- Patients who have received treatment for hematological pathology
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hematology department - UHMontpellier Saint éloi
Montpellier, France
Biospecimen
Blood and marrow
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
GUILLAUME CARTRON
University Hospital, Montpellier
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 22, 2014
First Posted
May 9, 2014
Study Start
February 1, 2014
Primary Completion (Estimated)
June 1, 2033
Study Completion (Estimated)
June 1, 2033
Last Updated
January 4, 2022
Record last verified: 2021-12